To accelerate progress on cardiometabolic diseases, it is essential to :

• Mobilize multidisciplinary experts and build strong partnerships between academia and industry to develop new tools,
• Identify new targets to create personalized medicine for cardiometabolic diseases,
• Implement public health policies dedicated to these diseases,
• Raising public awareness of this new scourge.

By organizing a symposium on cardiometabolic diseases, the Académie nationale de Médecine, the Inserm thematic institute and the IHU ICAN are seeking to bring together all those involved in the fight against cardiometabolic diseases (researchers, doctors, manufacturers, patient associations, biotech, public institutions, etc.).

The aim is to take stock of advances in research and identify the obstacles and actions required to accelerate research and improve the management of cardiometabolic diseases.

This symposium will give specialists in the field the opportunity to discuss these issues around 3 thematic round tables, illustrated by concrete case studies, and moderated by an expert in the field.

Plénière d’ouverture

• • Anne-Marie Armantéras, Présidente du conseil d’administration de l’IHU ICAN
  • Pr Christian Boitard, Secrétaire perpétuel de l’Académie nationale de médecine
  • Chantal Boulanger, Directrice de l’Institut thématique Physiopathologie, métabolisme et nutrition de l’Inserm

Table ronde n°1 : Les maladies cardiométaboliques, un enjeu de santé publique sous les radars

• • Modérateur : Pr Lionel Collet, Président de la Haute Autorité de Santé et membre titulaire de l’Académie nationale de médecine
  • Dr Catherine Grenier, Directrice des Assurés – Direction Déléguée à la Gestion et à l’Organisation des Soins – Caisse nationale de l’Assurance Maladie
  • Lionel Ribes, Président de l’Association Nationale des Hypercholestérolémies familiales et Lipoprotéines
  • Dr Caroline Semaille, Directrice Générale de Santé publique France

Table ronde n°2 : La prise en charge des maladies cardiométaboliques est-elle optimale ?

• • Modérateur : Jean-Noël Fiessinger, Professeur émérite de médecine vasculaire à Paris Cité et Vice-président de l’Académie nationale de médecine
  • Pr Judith Aron-Wisnewsky, Service de Nutrition – pôle cardiométabolisme – Hôpital Pitié-Salpétrière, UMRS 1269 NutriOmics – Sorbonne Université – IHU ICAN
  • Pr Bertrand Cariou, Directeur de l’institut du Thorax – Nantes Université, CHU Nantes, CNRS, Inserm
  • Dr Jean-François Thébaut, Cardiologue, Vice-président en charge du plaidoyer de la Fédération Française des Diabétiques

Table ronde n°3 : Quelles sont les avancées de la recherche sur les maladies cardiométaboliques ?

• • Modérateur : Pr Catherine Boileau, Professeure émérite de génétique, Université Paris Cité
  • Philip Janiak, PDG de Corteria Pharmaceuticals
  • Anne-Sophie Joly, Fondatrice du Collectif National des Associations
    d’Obèses
  • Dr Isabelle Lonjon Domanec, VP Clinical, Medical & Regulatory Affairs France de NovoNordisk
  • Pr Vlad Ratziu, Service de gastro-entérologie et hépatologie à l’Hôpital de la Pitié-Salpêtrière, Inserm UMR 1138, Centre de Recherche des Cordeliers – Sorbonne Université – IHU ICAN

Plénière de clôture

• • Pr Stéphane Hatem, Directeur général de l’IHU ICAN
  • Pr Michel Komajda, 1ère division de l’Académie de médecine – Maladies cardiovasculaires – Cardiologie
  • Nicolas Revel, Directeur général de l’AP-HP

Programme ;

09h30-09h45 : Accueil

09h45-10h00 : Introduction de la journée

10h00-10h30 : Pr. Jean-Sébastien Hulot (PARCC, Paris) Organoïdes cardiaque : de leur conception à leurs applications

10h30-10h45 : Shuai Luo (UMR-S 1180, Paris Saclay) Characterization of iPSC derived cardiomyocytes from patients with the CPVT RyR2^C2277R mutation.

10h45-11h15 : Pause café

11h15-11h45 : Dr. Nathalie Gaborit (Université de Nantes) – Deciphering the developmental origin of Brugada syndrome

11h45-12h00 : Dr. Jean-Michel Peyrin (Institut Biologie Paris Seine, Paris) – Acoustic levitation as a tool to manipulate cellular spheroids in laboratory or microgravity environment.

12h00-12h15 : Dr. Loan Vaillant-Beuchot (IRCAN, Nice) Caractérisation des effets de la mutation (p.Ser59Leu) dans les cardiomyocytes dérivés d’IPSCs de patients atteints d’une forme familiale de la sclérose latérale amyotrophique

12h15-12h30 : Présentation Sponsor : Stem Cell Technologies

12h30-14h00 : Déjeuner

14h00-14h30 : Dr. Eric Villard (UMR 1166/IHU ICAN, Paris) – Atouts et limites des cellules dérivées des iPSc pour la modélisation des maladies cardiovasculaires : l’expérience d’ICAN BioCell

14h30-14h45 : Simon Lledo (AMU – INSERM 1263 – INRAE 1260, Marseille) – Caractérisation de la réponse inflammatoire associée à la myocardite immuno-médiée dans un modèle de cardiomyocytes dérivés d’hiPSC

14h45-15h00 : Dr. Gaëlle Boncompain (Institut NeuroMyoGene, Lyon) – Adaptation of the secretory routes upon cell differentiation

15h00-15h15 : Pause café

15h15-15h30 : Dr. A Meli (PhyMedExp, Montpellier) Patient-derived neurocardiac organ-on-chip to model cardiopathies

15h30-16h00 : Dr. Pierre Joanne (Sorbonne Université, Paris) – Stem cell-derived cardiomyocytes and spheroids to study desmin-related cardiomyopathy

16h00-16h30 : Conclusion et discussion ouverte

The day was opened by Didier-Roland Tabuteau (Vice-President of the Conseil d’État), Marie-Laure Denis (President of the CNIL) and Stéphane Hatem (Managing Director of IHU ICAN).

3 round tables addressed the issues of AI use in research and medical practice, the regulatory framework for healthcare data and the economic ecosystem for this data in France.

Renaud Vedel (Director of Cabinet for Jean-Noël Barrot, Minister Delegate for Digital Transition and Telecommunications) and Thierry Tuot (Deputy Chairman of the Interior Section of the Conseil d’État) concluded the discussions, which were rich in proposals.

Photos ©JB Eyguesier/Conseil d’Etat.

The PEGASE project is aimed at patients with irreversible end-stage heart failure for whom there is a medical indication for transplantation but who cannot be transplanted because of the restrictive graft allocation policy. These patients suffer from end-stage heart failure and are in a therapeutic impasse. Their vital prognosis is directly engaged for lack of transplantation.

The course of the project

1. The heart is harvested from a donor eligible for cardiac harvesting, according to current recommendations and practices,
2. The heart transplant is transferred to Paris on a regular commercial flight according to the usual procedures,
3. Once it arrives at one of the airports in the Ile-de-France region, the graft is then transferred to the heart transplant center of the Pitié-Salpêtrière Hospital (Paris 13^e) to be transplanted into the recipient.

As an expert center in cardiac transplantation, the Pitié-Salpêtrière Hospital Group will be able to help patients waiting for a transplant benefit from this study. The PEGASE project is led by Pr Pascal Leprince (Head of the Cardiac and Thoracic Surgery Department) and his assistant Pr Guillaume Lebreton (Cardiac Surgeon).

The Agence de la biomédecine (ABM) is involved in the project to ensure that the rules of health safety, ethics and equity are respected.

In a context of organ shortage, the PEGASE project is a solid opportunity to increase the number of usable heart transplants for patients waiting for a heart transplant.

It would allow the transplantation of about ten additional hearts each year, which are currently not harvested for lack of a suitable preservation solution.

In addition, the proof of concept will open up other opportunities related to prolonged organ preservation and complex transplantation.

If you feel strongly about this cause, there are several ways you can support the PEGASE team and the participants of the IHU ICAN Hero Run.

All members of the IHU ICAN community are welcome to join us in this solidarity race (physicians, patrons, donors, partners, former employees…).

Your donations will support the 3-year pilot study, which aims to to provide this cardiac transplant to 7 patients with an indication for transplantationbut cannot currently be placed on the waiting lists because they do not meet the criteria for entry into the conventional system.

Thanks to the Run for Heroes 2023, our medical teams hope to raise the sum of 10 000€ to support the transplantation of one of these 7 patients.

One area of the application of Artificial Intelligence (AI) and Big Data is an ongoing challenge to public and private players: healthcare. It is a matter of finding a balance between data protection and around what is most intimate and most precious to the individual, his health, and society’s legitimate need for innovative treatments and diagnostics to meet medical needs that are insufficiently or poorly covered.

The collection and exploitation of massive data are very powerful levers for health research today, but they also call into question the current regulatory and organizational frameworks for research in France. The unavoidable need for protection, the mission of experimentation and innovation of public research in the short and medium term, and societal benefits in the long term: this is the triptych within which regulators and legislators must find a balance.

• Didier-Roland Tabuteau – Vice-President of the Council of State
• Marie-Laure Denis – President of the CNIL
• Stéphane Hatem – Director General of the ICAN HCI

• Thierry Tuot – Deputy President of the Interior Section of the Council of State

Artificial intelligence has made it possible to develop connected objects, essential tools for e-health. Through the illustration of the practical case of connected watches allowing to alert in real time a patient on his cardiac state of health, we will question their use, the interpretation of their results and the way in which they come to question, not only the ethics, but also the doctor-patient relationship. At the heart of the problem is medical decision making and the responsibility of the physician.

• Moderator: Gérard Biau – Managing Director of SCAI
• Stéphanie Combes – Director of the Health Data Hub
• Dominique Le Guludec – President of the HAS
• Pierre Jaïs – Director General of the IHU Liryc
• Valérie Paradis – PUPH at AP-HP

The usefulness of health data is no longer in question in the context of scientific health research protocols. Nevertheless, the question arises of the legal framework that must facilitate ambitious research projects without compromising the data protection framework. Their ownership, protection, anonymization, and regulatory harmonization raise essential regulatory issues whose implications have a direct impact on the quality of research. With the underlying question: How can we create legal data sanctuaries for reliable, quality research using health data?

• Moderator: Jean Lessi – Rapporteur to the Social Section of the Council of State
• Antonios Bouchagiar – Member of the Legal Service of the European Commission
• David Gruson – Founder of Ethik-IA
• Stéphane Hatem – Directeur général de l’ICAN HCI
• Valérie Peugeot – Commissioner responsible for health data at the CNIL

Once the regulatory framework is set, What ecosystem of bodies should ensure the preservation of the highly qualified data produced by the research centers? This richness, which is different from the data coming from the health care system (poured into the Health Data Hub), requires scientific competence, significant investments and a key element: trust. What is the profile of the regulator and/or sponsor of AI science research?

• Moderator: Louis Dutheillet de Lamothe – Secretary General of the CNIL
• Christian Deleuze – Deputy Chief Innovation Officer of Sanofi, President of Medicen Paris and President of the Healthcare Data Institute
• Yedidia Levy-Zauberman – Director of Public Affairs at Owkin
• Sébastien Massart – Director of Strategy at Dassault Systèmes

• Jean-Noël Barrot – Minister Delegate for Digital Transition and Telecommunications
• Thierry Tuot – Président adjoint de la section de l’intérieur du Conseil d’État

The event is accessible free of charge online, without pre-registration. You just have to connect at 9am on Friday, February 10, 2023 via one of the following media: